Scleroderma, Systemic

• 

  Subject Areas on Research

  • A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma. 
  • A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. 
  • Abnormal exhaled ethane concentrations in scleroderma. 
  • Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States. 
  • Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial. 
  • Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. 
  • Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. 
  • Anticentromere antibody. Clinical Correlations and association with favorable prognosis in patients with scleroderma variants. 
  • Apparent recurrence of progressive systemic sclerosis in a renal allograft. 
  • Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. 
  • Autologous Stem-Cell Transplantation for Severe Scleroderma. 
  • B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. 
  • B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. 
  • Barriers to care in juvenile localized and systemic scleroderma: an exploratory survey study of caregivers' perspectives. 
  • Brief Report: HLA-DRB1, DQA1, and DQB1 in Juvenile-Onset Systemic Sclerosis. 
  • CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. 
  • CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. 
  • Cadmium and lead in autopsy tissues. 
  • Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. 
  • Challenges in the diagnosis and treatment of juvenile systemic sclerosis. 
  • Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation. 
  • Circulating immune complexes in dermatologic disease. 
  • Clinical Characteristics and Factors Associated With Disability and Impaired Quality of Life in Children With Juvenile Systemic Sclerosis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. 
  • Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data. 
  • Clinical image: mandibular osteolysis secondary to systemic sclerosis. 
  • Cyclophosphamide in scleroderma lung disease. 
  • Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study. 
  • Development of a protocol for allogeneic marrow transplantation for severe systemic sclerosis: paradigm for autoimmune disease. 
  • Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. 
  • Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis. 
  • Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease. 
  • Endobronchial telangiectasias and hemoptysis in scleroderma. 
  • Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. 
  • Esophageal abnormalities in chronic graft-versus-host disease in humans. 
  • Esperanto for histones: CENP-A, not CenH3, is the centromeric histone H3 variant. 
  • Extracorporeal photochemotherapy: a potentially useful treatment for scleromyxedema. 
  • Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. 
  • Haemopoietic stem-cell transplantation for systemic sclerosis. 
  • High dose immunotherapy with stem cell rescue in severe systemic sclerosis: an idea that is moving forward. 
  • High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. 
  • High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. 
  • Induction of apoptosis in circulating angiogenic cells by microparticles. 
  • Inferior myocardial infarction complicated by mural thrombus and systemic embolization despite anticoagulation in progressive systemic sclerosis with normal coronary arteriograms. 
  • Large-Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung Fibrosis. 
  • Loss of Peristaltic Reserve, Determined by Multiple Rapid Swallows, Is the Most Frequent Esophageal Motility Abnormality in Patients With Systemic Sclerosis. 
  • Manufacture of Autologous CD34+ Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases. 
  • Mindin (SPON2) Is Essential for Cutaneous Fibrogenesis in a Mouse Model of Systemic Sclerosis. 
  • Mortality in primary and secondary myocarditis. 
  • Musculoskeletal syndromes associated with malignancy. 
  • Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures. 
  • Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. 
  • Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis. 
  • New prospects for autoimmune disease therapy: B cells on deathwatch. 
  • Niclosamide: Beyond an antihelminthic drug. 
  • Nodular amyloidosis in a patient with systemic scleroderma. 
  • Normal interleukin-7 (IL7) levels and normal IL7 response to CD4 T lymphopenia in patients with multiple sclerosis and systemic sclerosis. 
  • Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells. 
  • Nutritional support in patients with systemic scleroderma. 
  • Pain and Self-Efficacy Among Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. 
  • Perceived functioning has ethnic-specific associations in systemic sclerosis: another dimension of personalized medicine. 
  • Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. 
  • Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma. 
  • Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. 
  • Quantifying Skin Stiffness in Graft-Versus-Host Disease, Morphea, and Systemic Sclerosis Using Acoustic Radiation Force Impulse Imaging and Shear Wave Elastography. 
  • Quantitative genetic variation in CD19 expression correlates with autoimmunity. 
  • Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. 
  • Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial. 
  • Rheumatologic manifestations of cancer. 
  • Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension. 
  • Safety and efficacy of HSCT for systemic sclerosis across clinical trials. 
  • Sample size for a two-group comparison of repeated binary measurements using GEE. 
  • Scleroderma and IgG4-related disease. 
  • Self-management interventions in systemic sclerosis: A systematic review. 
  • Sexual activity and functioning in female scleroderma patients. 
  • Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. 
  • Stem Cell Therapy as a Treatment for Autoimmune Disease-Updates in Lupus, Scleroderma, and Multiple Sclerosis. 
  • Stem cell transplantation in systemic sclerosis. 
  • Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. 
  • T lymphocyte abnormalities in juvenile systemic sclerosis patients. 
  • Text data extraction for a prospective, research-focused data mart: implementation and validation. 
  • The 1978 annual meeting of the American Rheumatism Association. 
  • The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system. 
  • The basic and translational science year in review: Confucius in the era of Big Data. 
  • The combined effect of prazosin and autogenic training on cold reactivity in Raynaud's phenomenon. 
  • The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases. 
  • The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. 
  • The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. 
  • Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. 
  • Transcriptional regulation of Bim by FOXO3a and Akt mediates scleroderma serum-induced apoptosis in endothelial progenitor cells. 
• 

  Keywords of People

  • Craciunescu, Oana, Professor of Radiation Oncology, Radiation Oncology